NASDAQ:VERU

Veru Q4 2026 Earnings Date & Estimates

Veru logo
$1.94 -0.17 (-8.06%)
As of 03:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Veru is estimated to report Q4 2026 earnings on Wednesday, December 16, 2026, before market opens. The conference call is scheduled for December 18, 2026 at 12:30 PM ET.

Upcoming Earnings Announcement

Quarter
Q4 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET

What Analysts Expect from Veru in Q4 2026

Veru is expected to post earnings of -$0.34 per share. Veru last reported on August 10, 2026, posting -$0.30 per share and beating the -$0.32 consensus estimate. Veru has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.34

Recent Track Record

Last Reported
Q3 2026
Last Quarter EPS
-$0.30 (Beat by +$0.02)
EPS Beat Rate
7 of last 8 quarters

Veru Q4 2026 Earnings FAQ

Veru (NASDAQ:VERU) is estimated to report Q4 2026 earnings on Wednesday, December 16, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Veru's Q4 2026 earnings conference call is scheduled for Friday, December 18, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Veru to post earnings of -$0.34 per share for Q4 2026.

Veru's next earnings date is estimated for Thursday, November 26, 2026. MarketBeat tracks confirmed and estimated earnings dates for Veru on the company's earnings history page.

Veru Earnings Headlines

Veru (VERU) Projected to Announce Quarterly Earnings on Thursday
Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Veru Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email.

About Veru

Veru (NASDAQ:VERU) is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer.

The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.

Historically, Veru was known as The Female Health Company and developed FC2, a female condom distributed in the United States and internationally. The company adopted the Veru name in 2017 as it expanded its focus into pharmaceuticals.

View Veru Profile